IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITP IT Tech Packaging Inc

Pre-Mkt 05-11 06:11:26 EDT

0.1912

+0.0046

+2.47%

盘前0.1850

-0.0062-3.24%

04:27 EDT

High0.1943	Low0.1864	Vol342.66K
Open0.1900	D1 Closing0.1866	Amplitude4.23%
Mkt Cap3.24M	Tradable Cap3.14M	Total Shares16.97M
T/O65.04K	T/O Rate2.09%	Tradable Shares16.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.1912,"timestamp":1778270400000,"preClose":0.1866,"halted":0,"volume":342657,"hourTrading":{"tag":"盘前","latestPrice":0.185,"preClose":0.1912,"latestTime":"04:27 EDT","volume":2418,"amount":447.23758404,"timestamp":1778488058124,"change":-0.0062,"changeRate":-0.032427,"amplitude":0.000523},"delay":0,"changeRate":0.024651661307609974,"floatShares":16423703,"shares":16965420,"eps":-0.861876,"marketStatus":"Pre-Mkt","change":0.0046,"latestTime":"05-11 06:11:26 EDT","open":0.19,"high":0.1943,"low":0.1864,"amount":65040.53384052,"amplitude":0.042337,"askPrice":0.2101,"askSize":100,"bidPrice":0.1691,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.861876,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778506200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.1912,"preHourTrading":{"tag":"盘前","latestPrice":0.185,"preClose":0.1912,"latestTime":"04:27 EDT","volume":2418,"amount":447.23758404,"timestamp":1778488058124,"change":-0.0062,"changeRate":-0.032427,"amplitude":0.000523},"postHourTrading":{"tag":"盘后","latestPrice":0.19,"preClose":0.1912,"latestTime":"19:31 EDT","volume":9986,"amount":1903.5631,"timestamp":1778283072722,"change":-0.0012,"changeRate":-0.006276,"amplitude":0.006276},"volumeRatio":2.411759409509275,"impliedVol":1.8995,"impliedVolPercentile":0.836},"requestUrl":"/m/hq/s/ITP/wiki","defaultTab":"wiki","newsList":[{"id":"2633453731","title":"Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453731","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453731?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289829/0/en/Climb-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","PD","LU1169589451.USD","PK","LU1169590202.USD","ITP","BK4181","BK4077","SLE","BK4023","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633961311","title":"argenx Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633961311","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633961311?lang=en_us&edition=fundamental","pubTime":"2026-05-07 13:00","pubTimestamp":1778130000,"startTime":"0","endTime":"0","summary":"$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR antibody negative (“seronegative”) gMG PDUFA is May 10, 2026  Management to host conference cal","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289577/0/en/argenx-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","BK4208","BK4199","BK4585","LU0545039389.USD","LU2346227817.USD","LU0738911758.USD","LU2500361329.USD","BK4550","ITP","LU1003077747.HKD","BK4588","CMS","LU1894683348.USD","LU2637428348.USD","GD","LU1894683264.USD","LU0949170772.SGD","LU0170899867.USD","LU0661504455.SGD","LU0553294199.USD","BK4566","APM","BK4139","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633752152","title":"Bionano Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2633752152","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633752152?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:30","pubTimestamp":1778099400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  06, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano’s Board of Directors, has been appointed interim presiden","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3289425/0/en/Bionano-Announces-Leadership-Transition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910435","title":"Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910435","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910435?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:00","pubTimestamp":1777982400,"startTime":"0","endTime":"0","summary":"Overall, studies show: OGM Can Resolve Previously Unresolved Rare Disease CasesOGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV Sensit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287598/0/en/Bionano-Announces-a-56-Increase-in-Publications-Describing-the-Utility-of-OGM-in-Rare-Diseases-in-Q1-2026-vs-Q1-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMA","BK4196","BK4217","BK4590","WES","BK4211","BK4588","BK4179","BK4199","BK4589","WGS","CMA","NGS","BK4585","ITP","BK4144","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914063","title":"Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914063","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914063?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast T","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287504/0/en/Climb-Bio-Hosts-Budoprutug-R-D-Spotlight-Event-Highlighting-Topline-Subcutaneous-Formulation-Data-Broad-B-Cell-Mediated-Disease-Opportunity-and-Upcoming-Data-Readouts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","ITP","BK4199","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969366","title":"CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969366?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, May  04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287176/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4504","BK4585","LU1720051108.HKD","LU1917777945.USD","LU0742534661.SGD","BK4022","BK4516","IE00BSNM7G36.USD","LU1861558580.USD","LU1861559042.SGD","BK4139","LU2106854487.HKD","BK4532","LU0251131958.USD","LU0963586101.USD","BK4597","KSA","LU0868494617.USD","LU1974910355.USD","BK4199","BK4149","LU1064131342.USD","LU2357305700.SGD","CAR","LU2264538146.SGD","LU0868494708.USD","LU1720051017.SGD","BK4077","LU2237438978.USD","LU2023250504.SGD","LU1548497426.USD","IND","CAT","LU2543165471.USD","BK4520","SLE","LU0048573561.USD","UAE","ITP","LU0251142724.SGD","LU0942090050.USD","AGT","BK4611","SCD","CRSP","LU1988902786.USD","IE00BD6J9T35.USD","BK4230","FXI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629837806","title":"InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2629837806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629837806?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:20","pubTimestamp":1776950400,"startTime":"0","endTime":"0","summary":"BEIJING, April  23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3280053/0/en/InnoCare-Releases-2026-Q1-Results-Strong-Revenue-Growth-and-Sustained-Profitability.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4132","LU2089283258.USD","LU2271345857.HKD","BK4199","LU2111349929.HKD","BK4534","LU0795875086.SGD","LU0234570918.USD","LU2089284900.SGD","IE00BKVL7J92.USD","LU0912757837.SGD","LU1244550221.USD","LU0320765646.SGD","LU0006306889.USD","LU1244550577.SGD","LU0971096721.USD","BK4581","BK4504","LU0106831901.USD","BK4127","LU2023251221.USD","LU0225283273.USD","LU0882574139.USD","LU1720051017.SGD","LU1989772923.USD","LU0528227936.USD","SLE","ITP","LU0106261372.USD","LU2133065610.SGD","LU2357305700.SGD","AD","LU1162221912.USD","LU1732800096.USD","LU0158827948.USD","BK4516","LU1791710400.SGD","BK4588","LU0158827781.USD","LU1244550494.USD","LU1732799900.SGD","LU0314104364.USD","IBD","BK4077","LU0557290698.USD","LU0795875169.SGD","LU2028103732.USD","LU2347655156.SGD","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629779618","title":"IT Tech Packaging  receives notice of listing non-compliance with NYSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2629779618","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629779618?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:46","pubTimestamp":1776717968,"startTime":"0","endTime":"0","summary":"IT Tech Packaging (ITP)received an official notice of noncompliance from NYSE Regulation stating that the company is not in compliance with NYSE Am...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/it-tech-packaging-receives-notice-of-listing-non-compliance-with-nyse-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/it-tech-packaging-receives-notice-of-listing-non-compliance-with-nyse-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NYSE","BK4585","VGT","ITP","BK4588","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629020775","title":"IT Tech Packaging receives NYSE American notice after late filing of annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629020775","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629020775?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:18","pubTimestamp":1776716291,"startTime":"0","endTime":"0","summary":"IT Tech Packaging received NYSE American notice of noncompliance tied to late filing of its Form 10-K for year ended Dec. 31, 2025.Form 10-K missed April 15, 2026 deadline, triggering continued-listing deficiency process.NYSE notice has no immediate impact on listing or trading of ITP shares.Company expects to file report as soon as practicable, targeting completion within six-month cure period.Delay reflects inability to finalize financial results and related disclosures without unreasonable expense or effort, requiring additional time to complete financial statement review.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL4Z3wQn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629977577","title":"IT Tech Packaging, Inc. Announces Receipt of Notice of Non-Compliance With Nyse Continued Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2629977577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629977577?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:15","pubTimestamp":1776716112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN4130II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625949158","title":"Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949158","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949158?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:00","pubTimestamp":1775646000,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., April  08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3269976/0/en/Climb-Bio-to-Host-R-D-Spotlight-Webcast-Highlighting-Budoprutug-and-the-CD19-Opportunity-on-May-5-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4077","BK4218","HST","ITP","SLE","BK4199","BK4181","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624755447","title":"IT Tech Packaging delays filing annual report, cites unfinished financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2624755447","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624755447?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:03","pubTimestamp":1775001793,"startTime":"0","endTime":"0","summary":"IT Tech Packaging flagged a delay in filing its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Filing missed deadline as company had not finalized financial results or required disclosures.Company expects to file Form 10-K within 15 calendar days of prescribed due date.Management does not anticipate a significant change in results versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IT Tech Packaging Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL7QlHHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589931","title":"3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589931","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589931?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc.  today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both quantitative and qualitative growth: annual revenue hit RMB 17.7 billion, a historic breakthrough past the RMB 10 billion mark, representing a 94.3% year-on-year  increase; net profit attributable to shareholders of the parent company reached RMB 8.48 billion, surging 305.8% YoY; adjusted net profit attributable to shareholders of the parent company stood at RMB 8.45 billion, a 264.6% YoY rise. The company's profitability achieved a leap-forward growth, demonstrating robust growth momentum.Under the collaboration agreement, 3SBio granted Pfizer exclusive global development and commercialization rights to SSGJ-707, with the total potential deal value exceeding US$6 billion. The company is also entitled to tiered double-digi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/3sbio-announces-2025-annual-results-dual-engines-of-innovative-rd-and-global-collaboration-propel-revenue-past-rmb-10-billion-milestone-302729335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","LU1894683348.USD","BK1583","CLDT","PFE","BRVO","BK4568","IE00B19Z3581.USD","IND.AU","SLE","BK4592","BK7016","SG9999002232.USD","SG9999011175.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU1894683264.USD","SG9999013999.USD","LU0289739699.SGD","LU0170899867.USD","BK4534","LU0225284248.USD","LU0306806265.USD","LU0321505868.SGD","BK4585","LU1066053197.SGD","BK4581","SG9999001176.USD","ITP","01530","HK0000165453.HKD","BK4599","IE00BLSP4452.SGD","IBD","BK4077","BK1161","BK4588","SAA","ADA.AU","BK1593","LU0321505439.SGD","SG9999003800.SGD","IND","BK4181","LU1883839398.USD","BK4007","LU0456855351.SGD","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623370691","title":"Press Release: Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2623370691","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623370691?lang=en_us&edition=fundamental","pubTime":"2026-03-31 13:30","pubTimestamp":1774935000,"startTime":"0","endTime":"0","summary":"New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos. Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities. Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig. Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET. Gamgertamig  is a clinical--stage BCMAxCD3 T cell engager designed to enable rapid and deep plasma and B--cell depletion following a short duration, subcutaneously administered treatment course. In ongoing Phase 1/2 clinical studies, gamgertamig has demonstrated transformative efficacy and a differentiated safety profile after a single treatment cycle in severe antibody-mediated orphan diseases, including autoimmune hemolytic anemia  and immune thrombocytopenia . Gamgertamig has been granted both Fast Track ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199","BK4139","GLPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315283","title":"InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315283","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315283?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:48","pubTimestamp":1774864080,"startTime":"0","endTime":"0","summary":"The innovative drugmaker's newfound profitability marks its transition into a new stage characterized by stability and virtuous development cycles. Despite attracting strong market attention for its big business development deals, the company remains relatively undervalued. InnoCare now stands at a \"triple inflection point,\" with profitability achieved, globalization enhanced, and core pipelines progressed, marking a new stage in its development.InnoCare also differs from some of its peers that achieved early profitability by relying on one-time upfront payments from partnerships. By comparison, InnoCare's march to profitability has been jointly propelled by a dual engine of licensing deals and direct product sales. On the commercial front, the company's drug sales reached 1.44 billion yuan last year, up 43.4%.Orelabrutinib continued its strong momentum, now included on China's National Reimbursement Drug List for all four of its indications. Its approval as a first-line treatment for ","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/30/-30-3-2026-101148-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/30/-30-3-2026-101148-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/03/51532367/innocare-hits-profit-milestone-relative-undervaluation-points-to-stock-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/26/03/51532367/innocare-hits-profit-milestone-relative-undervaluation-points-to-stock-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0882574139.USD","LU1668664300.SGD","LU0006306889.USD","LU1548497426.USD","BK4199","LU1791710582.SGD","LU2089283258.USD","LU1791710400.SGD","LU0795875086.SGD","SLE","LU0106831901.USD","LU1720051108.HKD","LU2111349929.HKD","BK4585","LU1244550221.USD","LU0106261372.USD","LU1732800096.USD","LU0557290698.USD","LU1162221912.USD","BK4516","PCOM","BK4077","BK4122","BK4504","LU2133065610.SGD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU1244550494.USD","LU0320765646.SGD","LU0912757837.SGD","LU2028103732.USD","LU0795875169.SGD","LU0267386448.USD","BK4534","LU1244550577.SGD","LU0314104364.USD","ITP","LU2023251221.USD","LU1989772840.SGD","LU1989772923.USD","LU1074936037.SGD","LU0971096721.USD","LU1363072403.SGD","BK4581","LU2347655156.SGD","LU2357305700.SGD","IE00BKVL7J92.USD","LU2089284900.SGD","LU0158827781.USD","LU1720051017.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081422","title":"Press Release: Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081422","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081422?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 23, 2026  -- Bionano Genomics, Inc.  today reported financial results for the fourth quarter and full year ended December 31, 2025.For the three-month period ended December 31, 2025, as compared to the same period of 2024:. -- Reported total revenue of $8.0 million, representing a decrease of 3%. from $8.2 million in the fourth quarter of 2024.-- The prior year period included $2.8 million in instrument revenue,compared to $2.7 million in the fourth quarter of 2025.-- Sold 7,554 nanochannel array flowcells in the fourth quarter of 2025,representing a decrease of 6% over the 8,058 flowcells sold in the fourth. -- Installed 9 new OGM systems and brought 6 back to reach an installed base. of 387 at quarter-end, representing a 4% increase over the 371 installed. systems reported at the end of the fourth quarter of 2024.-- Generated gross margin of 43%, compared to 42% for the fourth quarter of. 2024, and non-GAAP gross margin1 of 43%, compared to 42% for the fourth. -- Rep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2500361329.USD","BK4121","CMS","LU2346227817.USD","LU2637428348.USD","LU0949170772.SGD","BK4208","ITP","LU1003077747.HKD","BNGO","TM","LU0661504455.SGD","BK4604","BK4588","BK4199","BK4575","LU1894683348.USD","LU1894683264.USD","BK4555","LU0553294199.USD","BK4099","LU0738911758.USD","BK4585","03160","LU0545039389.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620460844","title":"Argenx’s Long‑Term ITP Study Reaches Completion, Sharpening the Outlook for Efgartigimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2620460844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620460844?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:30","pubTimestamp":1773678613,"startTime":"0","endTime":"0","summary":"Argenx ($ARGX) announced an update on their ongoing clinical study. Argenx’s latest update covers a long‑term Phase 3 trial of efgartigimod in adul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenxs-long‑term-itp-study-reaches-completion-sharpening-the-outlook-for-efgartigimod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenxs-long‑term-itp-study-reaches-completion-sharpening-the-outlook-for-efgartigimod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617411075","title":"Press Release: Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617411075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617411075?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712000,"startTime":"0","endTime":"0","summary":"Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026. Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026. Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026. WELLESLEY HILLS, Mass., March 05, 2026  -- Climb Bio, Inc. , a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.previously treated patients with ITP is designed to evaluate safety,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","SLE","IND","BK4077","BK4539","ITP","BK4109","ASH","BK4139","CLYM","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614859660","title":"Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859660","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859660?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:00","pubTimestamp":1772197200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  27, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246483/0/en/Bionano-Symposium-2026-Concluded-with-9-Speakers-Describing-the-Breadth-of-Bionano-Solutions-and-Their-Potential-for-Use-on-a-Large-Scale.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","VGT","VIA","BK4585","BK4588","BK4179","BK4199","NGS","BK4023","ITP","CN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614044496","title":"10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044496","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044496?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:00","pubTimestamp":1772110800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitledOGM Making its Mark in Constitutional Gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245500/0/en/10-Presentations-on-Day-3-of-Bionano-Symposium-2026-Showcase-OGM-s-Utility-in-Unraveling-the-Complex-Puzzles-of-Constitutional-Genetic-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4144","ITP","BK4589","BK4199","BK4207","CMA","BK4196","BK4585","BK4590","WGS","BK4211","WES"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.itpackaging.cn","stockEarnings":[{"period":"1week","weight":-0.0343},{"period":"1month","weight":-0.0572},{"period":"3month","weight":-0.0581},{"period":"6month","weight":-0.2546},{"period":"1year","weight":-0.2947},{"period":"ytd","weight":-0.1257}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.000296},{"month":2,"riseRate":0.352941,"avgChangeRate":-0.00011},{"month":3,"riseRate":0.176471,"avgChangeRate":-0.025315},{"month":4,"riseRate":0.352941,"avgChangeRate":0.041526},{"month":5,"riseRate":0.294118,"avgChangeRate":-0.112858},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.03945},{"month":7,"riseRate":0.466667,"avgChangeRate":-0.042617},{"month":8,"riseRate":0.125,"avgChangeRate":-0.076512},{"month":9,"riseRate":0.4375,"avgChangeRate":0.011462},{"month":10,"riseRate":0.375,"avgChangeRate":0.03598},{"month":11,"riseRate":0.375,"avgChangeRate":0.097377},{"month":12,"riseRate":0.125,"avgChangeRate":0.001262}],"exchange":"AMEX","name":"IT Tech Packaging Inc","nameEN":"IT Tech Packaging Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IT Tech Packaging Inc,ITP,IT Tech Packaging Inc股票,IT Tech Packaging Inc股票老虎,IT Tech Packaging Inc股票老虎国际,IT Tech Packaging Inc行情,IT Tech Packaging Inc股票行情,IT Tech Packaging Inc股价,IT Tech Packaging Inc股市,IT Tech Packaging Inc股票价格,IT Tech Packaging Inc股票交易,IT Tech Packaging Inc股票购买,IT Tech Packaging Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}